Likmez

Phase 2Small molecule

SSaptalis Pharmaceuticals LLC

Likmez is one of 2 small molecule programs targeting Bacterial Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial InfectionNot yet recruiting

Bacterial InfectionPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Bacterial Infection

#DrugCompanyPhaseTrials

Likmez

SSaptalis Pharmaceuticals LLC

Phase 2

1 2

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Bacterial Infection

NCT07146217

Clinical

Trials by Indication[1]

Bacterial Infection1 trial

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Not yet recruiting·SSaptalis Pharmaceuticals LLC·Phase 2·NCT07146217·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Likmez. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Likmez compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Likmez. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Saptalis Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSaptalis Pharmaceuticals LLC

Likmez

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Bacterial Infection1 trial

References

Drug Info

Quick Facts

Related News